Renaissance Capital logo

Lucy Scientific Discovery Priced, Nasdaq: LSDI

Early-stage psychotropics contract manufacturing company.

Industry: Consumer Discretionary

Latest Trade: $1.46 0.00 (0.0%)

First Day Return: -25.3%

Return from IPO: -96.4%

Industry: Consumer Discretionary

We are an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. In August 2021, Health Canada’s Office of Controlled Substances granted us a Controlled Drugs and Substances Dealer’s Licence under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s Licence. The Dealer’s Licence, which we hold through one of our wholly owned subsidiaries, authorizes us to produce, assemble, sell, provide, transport, send, deliver, import or export (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Since current Canadian regulations prohibit the commercial sales of APIs and other products we intend to produce, APIs and other products we intend to produce would only be authorized for sale in Canada for clinical testing purposes in an “institution,” for the purpose of determining the hazards and efficacy of the drug, and for laboratory research in an institution by qualified investigators.
more less
IPO Data
IPO File Date 01/21/2022
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 1.9
Deal Size ($mm) $8
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/08/2023
Offer Price $4.00
Price Range $4.00 - $4.00
Offer Shares (mm) 1.9
Deal Size ($mm) $8
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
WestPark Capital
Company Data
Headquarters Victoria, Canada
Founded 2017
Employees 0
Website www.lucyscientific.com

Lucy Scientific Discovery (LSDI) Performance